Delving into the Latest Updates on LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesSkin and Musculoskeletal DiseasesOther Diseases

Active Indication-

Inactive Indication

Leishmaniasis, CutaneousPost-Kala-azar dermal leishmanioid

Originator Organization

Access To Advanced Health Institute

Active Organization-

Inactive Organization

Access To Advanced Health Institute

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to determine the efficacy, safety, and immunogenicity of an investigational vaccine being developed for the treatment of leishmaniasis, including cutaneous leishmaniasis (CL). The vaccine, identified as LEISH-F2 + MPL-SE, consists of a Leishmania protein (LEISH-F2) together with an adjuvant MPL-SE.

Start Date01 Oct 2009

Sponsor / Collaborator

Access To Advanced Health Institute

NCT00982774 / CompletedPhase 1IIT

Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in Combination With SSG in the Treatment of Patients With PKDL

A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of three injections of 10 µg LEISH-F2 + 25 µg MPL-SE given at 14-day intervals as an adjunct to standard chemotherapy with sodium stibogluconate (20 mg/kg/day for 40 days) in patients with PKDL.

Start Date01 Apr 2009

Sponsor / Collaborator

Access To Advanced Health Institute

100 Clinical Results associated with LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute)

Login to view more data

100 Translational Medicine associated with LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute)

Login to view more data

100 Patents (Medical) associated with LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute)

Login to view more data

100 Deals associated with LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Leishmaniasis, Cutaneous	Phase 2	PE	Access To Advanced Health Institute	01 Oct 2009
Post-Kala-azar dermal leishmanioid	Phase 1	SD	Access To Advanced Health Institute	01 Apr 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01011309 (CTgov)	Phase 2	Leishmaniasis, Cutaneous	45	MPL-SE (Immunotherapy v1.4/1.5)	ttqeyeblxb(jqkxftsmtl) = naikeoapgh gbhdfexwnw (wuutwysqai, vciwguywyu - plqrsmkqfx) View more	-	18 Nov 2013
				MPL-SE (Immunotherapy v1.6)	ttqeyeblxb(jqkxftsmtl) = nymmutjmeq gbhdfexwnw (wuutwysqai, wwejewpjwj - ikbheofgyw) View more